Relugolix in prostate cancer therapy: Clinical evidence and practical considerations
{{output}}
Introduction: Androgen deprivation therapy (ADT) remains a cornerstone of treatment for both localized and metastatic prostate cancer (PC). Relugolix, an oral gonadotrophin-releasing hormone antagonist, provides a new option for ... ...
